<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Open Forum Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Open Forum Infect Dis</journal-id><journal-id journal-id-type="publisher-id">ofid</journal-id><journal-id journal-id-type="hwp">ofids</journal-id><journal-title-group><journal-title>Open Forum Infectious Diseases</journal-title></journal-title-group><issn pub-type="epub">2328-8957</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">5781757</article-id><article-id pub-id-type="doi">10.1093/ofid/ofu052.533</article-id><article-id pub-id-type="publisher-id">ofu052</article-id><article-categories><subj-group subj-group-type="heading"><subject>IDWeek 2014 Abstracts</subject><subj-group subj-group-type="category-toc-heading"><subject>Poster Abstracts</subject></subj-group></subj-group></article-categories><title-group><article-title>825<break/>A Phase 3, Randomized, Double-Blind, Non-Inferiority Trial to Evaluate Efficacy and Safety of Isavuconazole vs Voriconazole in Patients with Invasive Mold Disease (IMD): Outcomes in Patients with Pulmonary Infections</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Raad</surname><given-names>Issam</given-names></name><xref ref-type="aff" rid="sa533-af1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mullane</surname><given-names>Kathleen M.</given-names></name><xref ref-type="aff" rid="sa533-af2">2</xref></contrib><contrib contrib-type="author"><name><surname>Selleslag</surname><given-names>Dominik</given-names></name><xref ref-type="aff" rid="sa533-af3">3</xref></contrib><contrib contrib-type="author"><name><surname>Thompson</surname><given-names>George</given-names></name><xref ref-type="aff" rid="sa533-af4">4</xref></contrib><contrib contrib-type="author"><name><surname>Neofytos</surname><given-names>Dionissios</given-names></name><xref ref-type="aff" rid="sa533-af5">5</xref><xref ref-type="aff" rid="sa533-af6">6</xref></contrib><contrib contrib-type="author"><name><surname>Shoham</surname><given-names>Shmuel</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="sa533-af5">5</xref></contrib><contrib contrib-type="author"><name><surname>Lee</surname><given-names>Misun</given-names></name><xref ref-type="aff" rid="sa533-af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Maher</surname><given-names>Rochelle</given-names></name><xref ref-type="aff" rid="sa533-af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Zeiher</surname><given-names>Bernhardt</given-names></name><xref ref-type="aff" rid="sa533-af7">7</xref></contrib><contrib contrib-type="author"><name><surname>Marty</surname><given-names>Francisco M.</given-names></name><xref ref-type="aff" rid="sa533-af8">8</xref></contrib></contrib-group><aff id="sa533-af1"><label>1</label>University of Texas MD Anderson Cancer Center, Houston, TX</aff><aff id="sa533-af2"><label>2</label>University of Chicago Medicine, Chicago, IL</aff><aff id="sa533-af3"><label>3</label>A.Z. Sint-Jan, Brugge, Belgium</aff><aff id="sa533-af4"><label>4</label>University of California, Davis, CA</aff><aff id="sa533-af5"><label>5</label>Johns Hopkins Hospital, Baltimore, MD</aff><aff id="sa533-af6"><label>6</label>Memorial Sloan-Kettering Cancer Center, New York, NY</aff><aff id="sa533-af7"><label>7</label>Astellas Pharma Global Development, Northbrook, IL</aff><aff id="sa533-af8"><label>8</label>Brigham and Women's Hospital, Boston, MA</aff><author-notes><fn id="TN189" fn-type="con"><p><bold>Session:</bold> 107. Clinical - Clinical Trials</p></fn><fn id="TN190" fn-type="con"><p>Friday, October 10, 2014: 12:30 PM</p></fn></author-notes><pub-date pub-type="ppub"><month>12</month><year>2014</year></pub-date><pub-date pub-type="epub" iso-8601-date="2014-12-01"><month>12</month><year>2014</year></pub-date><volume>1</volume><issue>Suppl 1</issue><issue-title>IDWeek 2014 Abstracts</issue-title><fpage>S236</fpage><lpage>S236</lpage><permissions><copyright-statement>&#x000a9; The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America</copyright-statement><copyright-year>2014</copyright-year></permissions><self-uri xlink:href="ofu052.533.pdf"/></article-meta></front><body><p><bold><italic>Background.</italic></bold>&#x02003;Isavuconazole (ISA) is a novel broad-spectrum triazole antifungal available as a water-soluble prodrug in IV and oral formulations for treatment of invasive fungal disease. A Phase 3 trial assessed the efficacy and safety of ISA vs voriconazole (VRC) in patients with IMD. Here we report outcomes in a pre-specified subset of patients from this non-inferiority trial, who had proven, probable, or possible pulmonary mold disease (PMD) without other site involvement (lower respiratory tract disease only).</p><p><bold><italic>Methods.</italic></bold>&#x02003;Patients were randomized 1:1 to receive ISA or VRC for up to 84 days. Dosing regimens were: ISA 200mg IV TID for 2 days, followed by 200mg QD (IV or PO); VRC 6mg/kg IV BID on Day 1, 4mg/kg IV BID on Day 2, then either 4mg/kg IV BID or 200mg PO BID. Eligibility criteria and pre-specified outcomes are available at clinicaltrials.gov, NCT00412893. The primary efficacy endpoint was all-cause mortality by Day 42. All-cause mortality on Day 84, overall success (complete + partial response) at end of treatment (EOT) determined by an independent blinded data review committee were recorded. Safety and tolerability were also assessed, as reported by the Investigator.</p><p><bold><italic>Results.</italic></bold>&#x02003;Overall 412 patients with proven/probable/possible PMD, primarily caused by <italic>Aspergillus</italic> spp. (n = 224), were enrolled. Patient characteristics, outcomes, and adverse events (AEs) are presented in the table. Outcomes in patients with proven/probable cases were similar to those with proven/probable/possible infections.
</p><table-wrap orientation="portrait" id="d35e214" position="float"><caption><p>Efficacy and safety in patients with PMD</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/><col align="left" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Parameter</th><th align="center" colspan="1" rowspan="1">ISA (n=200)</th><th align="center" colspan="1" rowspan="1">VRC (n=212)</th><th align="center" colspan="1" rowspan="1">Adjusted difference*
% (95% CI)</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">All-cause mortality on Day 42</td><td colspan="1" rowspan="1">34 (17)</td><td colspan="1" rowspan="1">44 (21)</td><td colspan="1" rowspan="1">&#x02212;2.9 (&#x02212;10.4, 4.6)</td></tr><tr><td colspan="1" rowspan="1">All-cause mortality on Day 84</td><td colspan="1" rowspan="1">55 (28)</td><td colspan="1" rowspan="1">68 (32)</td><td colspan="1" rowspan="1">&#x02212;3.8 (&#x02212;12.4, 4.8)</td></tr><tr><td colspan="1" rowspan="1">Overall success at EOT</td><td colspan="1" rowspan="1">82 (41)</td><td colspan="1" rowspan="1">89 (42)</td><td colspan="1" rowspan="1">&#x02212;1.8 (&#x02212;11.1, 7.4)</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Complete response</td><td colspan="1" rowspan="1">28 (14)</td><td colspan="1" rowspan="1">35 (17)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">&#x02003;Partial response</td><td colspan="1" rowspan="1">54 (27)</td><td colspan="1" rowspan="1">54 (25)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Stable</td><td colspan="1" rowspan="1">53 (27)</td><td colspan="1" rowspan="1">60 (28)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1">Progression</td><td colspan="1" rowspan="1">65 (33)</td><td colspan="1" rowspan="1">63 (30)</td><td colspan="1" rowspan="1"/></tr><tr><td colspan="1" rowspan="1"><italic>Safety</italic></td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">P value</td></tr><tr><td colspan="1" rowspan="1">&#x02003;AEs</td><td colspan="1" rowspan="1">194 (97)</td><td colspan="1" rowspan="1">210 (99)</td><td colspan="1" rowspan="1">0.2</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Study drug-related AEs</td><td colspan="1" rowspan="1">85 (43)</td><td colspan="1" rowspan="1">130 (61)</td><td colspan="1" rowspan="1">&#x0003c;0.001</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Serious AEs</td><td colspan="1" rowspan="1">108 (54)</td><td colspan="1" rowspan="1">128 (60)</td><td colspan="1" rowspan="1">0.2</td></tr><tr><td colspan="1" rowspan="1">&#x02003;Study drug-related serious AEs</td><td colspan="1" rowspan="1">24 (12)</td><td colspan="1" rowspan="1">27 (13)</td><td colspan="1" rowspan="1">0.9</td></tr><tr><td colspan="1" rowspan="1">&#x02003;AE leading to permanent discontinuation</td><td colspan="1" rowspan="1">33 (17)</td><td colspan="1" rowspan="1">53 (25)</td><td colspan="1" rowspan="1">0.04</td></tr></tbody></table><table-wrap-foot><fn id="TN191" fn-type="con"><p>*(ISA&#x02013;VRC)</p></fn></table-wrap-foot></table-wrap><p><bold><italic>Conclusion.</italic></bold>&#x02003;ISA had comparable efficacy to VRC for the primary treatment of PMD patients, but had a lower rate of drug-related AEs vs VRC</p><p><bold><italic>Disclosures.</italic></bold>&#x02003;<bold>I. Raad</bold>, Atellas: Grant Investigator, Grant recipient; Pfizer: Consultant, Consulting fee <bold>K. M. Mullane</bold>, Astellas Pharma US, Inc.: Research Contractor and Speaker's Bureau, Research support; Anson Pharmaceuticals: Research Contractor, Research support; Chimerix: Research Contractor and Scientific Advisor, Research support Cubist/Optimer: Research Contractor, Scientific Advisor and Speaker's Bureau, Consulting fee, Research support and Speaker honorarium; Merck Sharp and Dohme Corp: Research Contractor and Scientific Advisor, Consulting fee and Research support; Rebiotix: Research Contractor, Research support; ViroPharma: Research Contractor, Research support; Pfizer: Research Contractor, Research support <bold>D. Selleslag</bold>, Pfizer: Investigator and Speaker's Bureau, Educational grant, Research grant and Speaker honorarium; MSD: Investigator and Scientific Advisor, Consulting fee and Research support; Astellas: Investigator, Research support <bold>G. Thompson</bold>, Astellas: Scientific Advisor, Consulting fee <bold>D. Neofytos</bold>, Astellas: Consultant and Scientific Advisor, Consulting fee and Speaker honorarium; Roche Diganostics: Scientific Advisor, Consulting fee; Pfizer: Research Contractor, Research grant <bold>S. Shoham</bold>, Astellas: Scientific Advisor, Research support; Merck: Grant Investigator, Grant recipient and Research support; Pfizer: Investigator, Research support <bold>M. Lee</bold>, Astellas: Employee, Salary <bold>R. Maher</bold>, Astellas Pharma Global Development: Employee, Salary <bold>B. Zeiher</bold>, Astellas: Employee, Salary <bold>F. M. Marty</bold>, Astellas: Grant Investigator, Research support; Chimerix: Grant Investigator, Research support; Merck: Consultant, Consulting fee; Vertex: Consultant, Consulting fee; Whiscon: Grant Investigator, Research support; Alexion: Consultant, Consulting fee; Gilead: Consultant, Consulting fee; ViroPharma: Grant Investigator, Research support; GlaxoSmithKline: Grant Investigator, Research support</p></body></article>